Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: CAR-T, CD19 Jul 16 | 2021Autolus Appoints Edgar Braendle as Chief Development OfficerAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Jul 02 | 2021First Patient Dosed With Precision’s Stealth Cell PBCAR19BAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T Jul 01 | 2021Allogene’s TurboCAR ALLO-605 Receives Fast Track Designation From the FDAAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jun 29 | 2021Gilead’s Ph3 ZUMA-7 Trial Demonstrates Improved Efficacy of Yescarta vs SoC in 2L DLBCL; Which CD19 CAR-T Treating DLBCL Will Move Into an Earlier Line of Therapy First? First Patient Dosed With Precision’s PBCAR269A + Nirogacestat CombinationAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jun 28 | 2021Thoughts on Abecma’s Positive CHMP Opinion for a Conditional Approval in ≥4L R/R MMAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jun 25 | 2021CHMP Adopts Positive Opinion for BMS’s Abecma in ≥4L r/r MMAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 23 | 2021Yescarta / FKC876 Approved in China for Adult Patients With ≥3L R/R DLBCLAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jun 23 | 2021JNJ / Legend Announce a New EU Manufacturing Site in BelgiumAccess Free BlastFree
Posted in: Allogeneic, CAR-T Jun 22 | 2021Allogene Overland Appoints Shuyuan Yao as CEOAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jun 22 | 2021Will Abecma Receive a Positive CHMP Opinion on June 24? BMS Seeks a Clock-Stop Extension for Breyanzi; CHMP Agenda June 2021Access Free BlastFree
Posted in: Allogeneic, TCR Jun 19 | 2021Thoughts on Gilead’s Collaboration with Shoreline to Develop iPSC-derived Allogeneic Cell TherapiesAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jun 17 | 2021Will Abecma Receive a Positive CHMP Opinion by June 24? Breyanzi’s EU Regulatory Delay Continues; CAT Agenda June 2021Access Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 Jun 15 | 2021Gracell’s GC012F US and Chinese IND in MM Planned for H1 2022: Could Gracell Leverage Data From Chinese Trials to Accelerate Their Clinical Programs in the US? Autolus's Obe-cel Receives ILAP Designation in r/r Adult ALLAccess Free BlastFree
Posted in: CAR-T, CD19 Jun 13 | 2021Yescarta Outperforms SoC in a Matched Analysis of ZUMA-5 in r/r FL; Tecartus’s Improved Safety Profile in the Ph1/2 ZUMA-4 Trial; Breyanzi’s Ph2 OUTREACH Trial Demonstrates the Feasibility of Outpatient Administration; Obe-cel Reports a Possible Best-in-Class Profile for Adult ALL; Mustang Bio’s MB-106 Reports a 93% ORR in NHL; EHA 2021 Day 3Access Free BlastFree
Posted in: BCMA, CAR-T, Dual/triple agonist Jun 12 | 2021Cilta-cel Demonstrates Improved Efficacy in Matched Analyses vs SoC; Cilta-cel’s New CARTITUDE-5 Trial in NDMM; Anakinra Prophylaxis Fails to Improve Orva-cel’s Safety Profile; Initial Clinical Data from Celyad’s CYAD-211 BCMA CAR-T; Gracell’s Investor Event: Will MRD Negativity Become a New Surrogate Marker? Updated Clinical Data from IASO’s CT103A; EHA 2021 Day 2Access Free BlastFree
Posted in: CAR-T, CD19 Jun 11 | 2021Yescarta More Cost-Effective Compared to Kymriah but With Higher CRS and NT Rates; Updated Results From Kymriah’s Ph1b PORTIA Trial; POC CD19 CAR-Ts Outperform OOS Kymriah; EHA 2021 Day 1Access Free BlastFree
Posted in: CAR-T, CD19 Jun 10 | 2021BMS Reports Positive Topline Results From Breyanzi’s Ph3 TRANSFORM Trial in 2L DLBCL vs SoC: Will Breyanzi be the First Approved CAR-T in 2L DLBCL?Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jun 09 | 2021Cilta-cel Continues to Demonstrate Best-in-Class Efficacy With an Improved Safety Profile; Abecma’s Efficacy in Hard-to-Treat Subgroups; Could Gracell’s FasTCAR GC012F (BCMA x CD19) Further Decrease TATs? Thoughts on Arcellx’s Initial Results From CART-ddBCMA; ASCO 2021 Day 4Access Free BlastFree
Posted in: Autologous, CAR-T, CD19, CD22, Dual/triple agonist Jun 08 | 2021Results from Kymriah’s Ph2 ELARA Trial; When Could Kymriah Become Approved in FL? Is Retreatment With Yescarta Commercially Feasible? CBMG Highlights Results From C-CAR066 and C-CAR039; ASCO 2021 Day 3 Part IIAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.